Welcome back to another edition of Endpoints Weekly. We had another busy week chock-full of news, so let’s jump into the headlines. We kick off this week with founding editor ...
RFK Jr. advisor Calley Means challenges drugmakers considering pulling their investment in the US over Trump's most favored nations plan, calling it 'morally reprehensible.'
The fate of a small, privately-held biotech’s new drug has been delayed, in what appears to be a sign that broad cuts to the FDA by the Trump administration may ...
During Thursday’s first-quarter earnings call, Chris Boerner made his strongest comments yet that Bristol Myers intends to be active at the dealmaking table this year.
The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, saying they are not an effective tool to onshore drug manufacturing to the US.
The fallout comes amid a yearslong slog for biotech, which has struggled since high interest rates and inflation curbed what was a booming market during the Covid-19 pandemic.
FDA faces major shakeup as CBER chief Peter Marks exits, Trump admin implements cuts across HHS, and new tariff plan creates industry confusion. Sens. Cassidy and Sanders seek answers.
FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop. Moderna down 11%, Sarepta down 7.5%, uniQure down 20%.
